XINT.ST

Xintela AB (publ) [XINT.ST] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

XINT.ST Stock Summary

Top 10 Correlated ETFs

XINT.ST

Top 10 Correlated Stocks

XINT.ST

In the News

XINT.ST Financial details

Company Rating
-
Market Cap
159.33M
Income
-54.72M
Revenue
78K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
25
Optionable
No
Shortable
Yes
Earnings
24 May 2024
P/E
-1.44
Forward P/E
-
PEG
0.26
P/S
-
P/B
10.17
P/C
-
P/FCF
-6.29
Quick Ratio
0.95
Current Ratio
1.48
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.16
EPS next Y
-
EPS next Q
-
EPS this Y
-64.86%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-26.6%
Revenue last 5Y
15.47%
Revenue Q/Q
-
EPS Q/Q
39.5%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-287%
ROE
952%
ROC
-8.12%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.2-0.35
52W High
-
52W Low
-
RSI
54
Rel Volume
2.25
Avg Volume
261.52K
Volume
588.63K
Perf Week
17.14%
Perf Month
7.33%
Perf Quarter
-1.91%
Perf Half Y
-10.87%
-
-
-
-
Beta
1.642
-
-
Volatility
0.04%, 0.07%
Prev Close
1.23%
Price
0.41
Change
-6.82%

Something similar

Top by Market Cap
AAPL
AMZ.DE
VOO
V
LLY
Top Correlated ETFs
HDGB.L
SMGB.L
EALU.MI
HTWG.L
ROBG.L
Top Correlated Stocks
2219.HK
1822.HK
0840.HK
2197.HK
FLK.L
Similar Market Cap
OTPIX
SRNE
HFFG
ONL
PRTH

Company Profile

Healthcare Biotechnology
  • Volume Average 261.52K
  • Market Capitalization 159.33M
  • Employee 25
  • CEO Dr. Evy Lundgren-Åkerlund Assoc.Prof, BSc, Ph.D.
  • Headquarters Lund,SE
  • IPO Date 2016-03-22
  • Website https://www.xintela.se

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.